PharmX Technologies (ASX:PHX) EBIT: A$-0.71 Mil (TTM As of Dec. 2025)

What is PharmX Technologies EBIT?

PharmX Technologies ASX:PHX 40 EBIT is A$-0.71 Mil as of Dec. 2025. GuruFocus rates ASX:PHX with a GF Score™ of 40/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review.

PharmX Technologies's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was A$-0.42 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.71 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PharmX Technologies's annualized ROC % for the quarter that ended in Dec. 2025 was -7.10%. PharmX Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -67.50%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PharmX Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -0.85%.

PharmX Technologies (ASX:PHX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PharmX Technologies's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	-0.974 * ( 1 - 0% )	/	( (13.586	+	13.854)	/ 2 )
=	-0.974	/	13.72
=	-7.10 %

where

	Invested Capital		(Q: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	18.825	-	1.211	-	( 4.172	-	max(0, 1.73	-	5.758	+	4.172	))
=	13.586

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	18.006	-	0.938	-	( 3.214	-	max(0, 1.419	-	5.227	+	3.214	))
=	13.854

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

PharmX Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2025		Q: Dec. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.838	/	( ( (0.806 + max(0.074, 0))	+	(0.686 + max(0.917, 0)) )	/	2 )
=	-0.838	/	( ( 0.88	+	1.603 )	/	2 )
=	-0.838	/	1.2415
=	-67.50 %

where Working Capital is:

	Working Capital		(Q: Jun. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.981	+	0	+	0.469)	-	(1.211	+	0.028	+	0.137)
=	0.074

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.298	+	0	+	0.715)	-	(0.938	+	0	+	0.158)
=	0.917

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PharmX Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2025 )
	=	-0.711	/	83.236
	=	-0.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmX Technologies EBIT Related Terms

PharmX Technologies EBIT Historical Data

* Premium members only.

The historical data trend for PharmX Technologies's EBIT can be seen below:

PharmX Technologies EBIT Chart

PharmX Technologies Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

EBIT

Get a 7-Day Free Trial

1.50

0.37

-0.67

0.24

0.11

PharmX Technologies Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
EBIT	Get a 7-Day Free Trial															0.44	-0.19	0.40	-0.29	-0.42

ASX:PHX vs VEEV, BTSG, TEM: EBIT Comparison

For the Health Information Services subindustry, PharmX Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmX Technologies EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PharmX Technologies's EV-to-EBIT falls into.

Save Embed

40GF Score

PharmX Technologies Ltd ASX:PHX

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

PharmX Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.71 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of A$-0.71 Mil mean?

PharmX Technologies (ASX:PHX) has a EBIT of A$-0.71 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PharmX Technologies.

Is PharmX Technologies' EBIT too high?

PharmX Technologies' current EBIT is A$-0.71 Mil. Overall, PharmX Technologies has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does PharmX Technologies' EBIT compare to VEEV and BTSG?

PharmX Technologies' EBIT of A$-0.71 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Healthcare Providers & Services company?

A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PharmX Technologies. PharmX Technologies's current EBIT is A$-0.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is PharmX Technologies stock overvalued right now?

Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.13 — trading 85.7% above its estimated fair value. The current EBIT is A$-0.71 Mil. PharmX Technologies' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current EBIT is A$-0.71 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmX Technologies (ASX:PHX) Overvalued in 2026?

Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued. The current stock price of A$0.13 is trading 85.7% above its estimated GF Value™ of A$0.07. GuruFocus considers PharmX Technologies to be Significantly Overvalued.

Key valuation signals for ASX:PHX:

EBIT: A$-0.71 Mil
GF Value™: A$0.07 vs. price of A$0.13 (85.7% above fair value)
GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmX Technologies Business Description

Industry Healthcare Healthcare Providers & Services

Comparable Companies ASX:M7T ASX:BB1 ASX:SHG ASX:EMD ASX:PCK ASX:TRI ASX:BMT ASX:ALC ASX:PKY ASX:RHT VEEV BTSG ASX:PME TEM HQY TSE:2413 HKSE:02228 HNGE DOCS WAY

Address 17 Castlereagh Street, Suite 11.02, Level 11, Sydney, NSW, AUS, 2000

Website https://www.pharmx.com.au

PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.

40GF Score

Get the complete analysis for ASX:PHX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.13

Price

A$0.07

GF Value

View ASX:PHX Analysis

See EBIT data for all stocks →